The Patent Finder

Terms ending in 2028

Intervet Inc.

Every in-force patent on Intervet Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,980,283C. perfringens alpha toxoid vaccine
In force
 · High confidence
Intervet Inc.In forceHigh confidence
US 7,732,187Recombinant Attenuated Clostridium Organisms and Vaccine
In force
 · High confidence
Intervet Inc.In forceHigh confidence
US 9,593,303Method for Continuously Culturing Ehrlichia and Neorickettsia Risticii
In force
 · High confidence
Intervet Inc.In forceHigh confidence
US 12,324,657System and Method for Diagnosis of Bovine Diseases Using Auscultation Analysis
In force
 · High confidence
Intervet Inc.In forceHigh confidence
US 8,791,242Canine Thymic Stromal Lymphopoietin Protein and Uses Thereof to Treat Allergic Symptoms
In force
 · High confidence
Intervet Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited